For Institutional Investors in the US

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst
Daniel Lyons, Ph.D., CFA | Janus Henderson Investors

Daniel Lyons is a Portfolio Manager and Research Analyst at Janus Henderson Investors responsible for co-managing the Biotechnology strategy since 2018. Dr. Lyons started consulting for Janus in 1997 and joined the Health Care Sector Research Team full time in 2000. As a research analyst, he focuses on the biotechnology and life science tools sectors.

Dr. Lyons received his bachelor of arts degree in biochemistry and chemistry from Rice University, graduating magna cum laude. He also earned a Ph.D. from Stanford University’s program in immunology and conducted postdoctoral research with a Nobel Laureate at the University of Colorado. He holds the Chartered Financial Analyst designation and has 21 years of financial industry experience.

Articles Written

COVID Variants: The Impact on Pandemic Trajectory, Biopharma Stocks

COVID Variants: The Impact on Pandemic Trajectory, Biopharma Stocks

Making sense of the latest developments around COVID-19 variants and what investors should consider now.

COVID-19 Vaccine Beats Expectations
Quick Views Coronavirus Healthcare

COVID-19 Vaccine Beats Expectations

How a novel vaccine candidate from Pfizer and BioNTech could shape the trajectory of the global pandemic.